Modality
Degrader
MOA
PLK4i
Target
USP1
Pathway
Complement
Parkinson'sCervical CaLN
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
Nov 2018
→ Feb 2026
Phase 1Current
NCT04580928
184 pts·Cervical Ca
2023-11→TBD·Completed
NCT06331033
1,414 pts·LN
2018-11→2026-02·Completed
1,598 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-141mo agoPh2 Data· LN
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Complet…
P1/2
Complet…
Catalysts
Ph2 Data
2026-02-14 · 1mo ago
LN
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04580928 | Phase 1/2 | Cervical Ca | Completed | 184 | PFS |
| NCT06331033 | Phase 1/2 | LN | Completed | 1414 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Tezesotorasib | Enliven | Phase 2 | USP1 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| ETN-5063 | 89bio | Phase 1/2 | USP1 | |
| CSL-7919 | CSL Limited | Preclinical | BTK | |
| RDY-3640 | Dr Reddy's | Preclinical | EZH2 | |
| Rimatuximab | Boehringer Ingelheim | Phase 2/3 | PLK4 | |
| Miritapinarof | Luye Pharma | Phase 2 | IL-17A |